Starting or Strengthening a Drug Bulletin - A Practical Manual
(2005; 165 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentHow the manual was produced
View the documentAbout ISDB
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Rational use of medicines
Open this folder and view contents3. What are drug bulletins?
Open this folder and view contents4. Defining aims, target and type of bulletin
Open this folder and view contents5. Planning resources
Open this folder and view contents6. Planning bulletin production: schedules and timing
Close this folder7. The editorial process
View the document7.1 Outline of the editorial process
Open this folder and view contents7.2 Editing a drug bulletin
Open this folder and view contents7.3 Writing bulletin articles
Open this folder and view contents7.4 Reviewing the article
View the document7.5. Rewriting the article
View the document7.6 Final checks
Close this folder7.7 Follow-up after publication
View the document7.7.1 Indexing
View the document7.7.2 Authors’ certificates
View the document7.7.3 Post-publication correspondence
View the document7.7.4 Corrections
View the document7.7.5 Requests for reproduction
View the document7.7.6 Keeping track of how bulletin articles are quoted and used
View the document7.8 References
Open this folder and view contents8. Reviewing a new drug: is it a therapeutic advance?
Open this folder and view contentsAnnexe to Chapter 8: Evaluating harm
Open this folder and view contents9. Design and production
Open this folder and view contents10. Dissemination
Open this folder and view contents11. Organizational and legal issues
Open this folder and view contents12. Evaluating quality and usefulness
Open this folder and view contents13. Partnership and collaboration
Open this folder and view contents14. Keeping records and creating a memory
Open this folder and view contentsAppendix: Electronic sources of information

7.7.5 Requests for reproduction

When a bulletin becomes well known nationally or internationally, it begins to receive requests for reproduction of its articles. These may come from other bulletins or other periodicals, patients’ associations or organizations for continuing education, in which case they cause little or no difficulty. However, they may also come from the pharmaceutical industry or industry-sponsored institutions. This requires more caution. The editorial team needs to know how a reprint will be used, for example, whether it will be used to promote a drug, or to attack a competitor’s product.

The bulletin needs a clear policy on how to deal with such situations. Some ISDB bulletins have a written policy for reproduction of their articles (e.g. Drug and Therapeutics Bulletin, UK; la revue Prescrire, France). You need to make sure that the article will not be shortened, or a section reproduced out of context, and that the source will be mentioned. One concern is whether a reprint by a pharmaceutical company gives the impression of a link between this firm and the bulletin. One way used by bulletins to deal with this risk is that the bulletin produces reprints, sells them at cost to the company (i.e. without profit) and puts a stamp on the reprint saying: “Reprinted and sold at cost by [name of the bulletin]”.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017